Regenerative Therapies for Parkinson's Disease: An Update.

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Thomas B Stoker, Roger A Barker

Abstract

Parkinson's disease is the second most common neurodegenerative disorder. It is characterised by a typical movement disorder that occurs in part because of the selective degeneration of the dopaminergic neurons of the substantia nigra pars compacta. Current treatment for the motor disorder of Parkinson's disease consists of dopaminergic medications, but these come with significant adverse effects, themselves an important part of the clinical course of Parkinson's disease, particularly in advanced stages. Therefore, treatment is needed that can restore dopaminergic tone in the striatum in a physiological and targeted manner to avert these side effects. A number of potential regenerative treatments have been developed with a view to achieving this. Following decades of optimisation and development of stem-cell-based treatments and viral gene delivery, clinical trials are on the horizon. For these treatments to be widely useful, they must be clinically effective, cost efficient and safe, and a number of practical aspects regarding storage and delivery of treatment must be optimised. Many barriers have been overcome, and the field of regenerative medicine for Parkinson's disease is now increasingly focussed on how these treatments ...Continue Reading

References

Jan 1, 1990·Movement Disorders : Official Journal of the Movement Disorder Society·C WatersL P Weiner
Jan 1, 1988·Progress in Brain Research·R Drucker-ColínC Torres
Jan 1, 1988·Progress in Brain Research·S S JiaoM T Shi
Mar 21, 1996·Nature·D M GashG A Gerhardt
Aug 28, 1997·Nature·M G SpillantiniM Goedert
Nov 6, 1998·Science·J A ThomsonJ M Jones
Mar 10, 2001·The New England Journal of Medicine·C R FreedS Fahn
Sep 4, 2003·Annals of Neurology·C Warren OlanowThomas B Freeman
Feb 18, 2005·Journal of Neurochemistry·Chang-Hwan ParkSang-Hun Lee
Jan 16, 2007·Journal of Neurology, Neurosurgery, and Psychiatry·Adolfo Mínguez-CastellanosJosé López-Barneo
Dec 15, 2007·Nature Protocols·Kazutoshi TakahashiShinya Yamanaka
Sep 18, 2009·Brain : a Journal of Neurology·M SelikhovaA J Lees
Jan 29, 2010·Nature·Thomas VierbuchenMarius Wernig
Feb 5, 2010·Translational Research : the Journal of Laboratory and Clinical Medicine·Neelam K VenkataramanaSatish M Totey
Jul 2, 2010·Science Translational Medicine·Marios PolitisPaola Piccini
Jul 8, 2010·Molecular Therapy : the Journal of the American Society of Gene Therapy·Shin-ichi MuramatsuImaharu Nakano
May 20, 2011·Journal of Neurology, Neurosurgery, and Psychiatry·Jonathan R EvansRoger A Barker
May 26, 2011·Movement Disorders : Official Journal of the Movement Disorder Society·Marios PolitisPaola Piccini
Apr 18, 2012·Movement Disorders : Official Journal of the Movement Disorder Society·Ronald B PostumaTjalf Ziemssen

❮ Previous
Next ❯

Citations

Jul 10, 2019·Journal of Parkinson's Disease·Stephen Polgar, Sheeza Mohamed

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT01898390
NCT03119636

Related Concepts

Related Feeds

CREs: Gene & Cell Therapy

Gene and cell therapy advances have shown promising outcomes for several diseases. The role of cis-regulatory elements (CREs) is crucial in the design of gene therapy vectors. Here is the latest research on CREs in gene and cell therapy.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Current Opinion in Neurology
Brian J Snyder, C Warren Olanow
Experimental Neurology
Aleksandra Glavaski-Joksimovic, Martha C Bohn
Journal of Controlled Release : Official Journal of the Controlled Release Society
Jodie H K ManMassimiliano Caiazzo
© 2022 Meta ULC. All rights reserved